WVE

Company Overview — What Does Wave Life Sciences Ltd. Do?

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore. Wave Life Sciences Ltd. (WVE) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Paul B. Bolno and employs approximately 240 people, headquartered in Singapore, Massachusetts. With a market capitalization of $1.3B, WVE is one of the notable companies in the Healthcare sector.

Wave Life Sciences Ltd. (WVE) Stock Rating — Reduce (April 2026)

As of April 2026, Wave Life Sciences Ltd. receives a Reduce rating with a composite score of 30.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.WVE ranks #3,843 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Wave Life Sciences Ltd. ranks #649 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

WVE Stock Price and 52-Week Range

Wave Life Sciences Ltd. (WVE) currently trades at $7.15. The stock lost $0.01 (0.1%) in the most recent trading session. The 52-week high for WVE is $21.73, which means the stock is currently trading -67.1% from its annual peak. The 52-week low is $5.28, putting the stock 35.4% above its annual trough. Recent trading volume was 1.9M shares, reflecting moderate market activity.

Is WVE Overvalued or Undervalued? — Valuation Analysis

Wave Life Sciences Ltd. (WVE) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.58x, versus the sector average of 2.75x. The price-to-sales ratio is 75.07x, compared to 1.66x for the average Healthcare stock.

At current multiples, Wave Life Sciences Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Wave Life Sciences Ltd. Profitability — ROE, Margins, and Quality Score

Wave Life Sciences Ltd. (WVE) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -41.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -33.4% versus the sector average of -33.1%.

On a margin basis, Wave Life Sciences Ltd. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -630.0% (sector: -66.1%). Net profit margin stands at -599.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -61.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

WVE Debt, Balance Sheet, and Financial Health

Wave Life Sciences Ltd. has a debt-to-equity ratio of 22.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.47x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $196M.

WVE has a beta of 1.52, meaning it is more volatile than the broader market — a $10,000 investment in WVE would be expected to move 51.7% more than the S&P 500 on any given day. The stability factor score for Wave Life Sciences Ltd. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Wave Life Sciences Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Wave Life Sciences Ltd. reported revenue of $18M and earnings per share (EPS) of $-1.21. Net income for the quarter was $-213M. Gross margin was 100.0%. Operating income came in at $-223M.

In FY 2025, Wave Life Sciences Ltd. reported revenue of $43M and earnings per share (EPS) of $-1.21. Net income for the quarter was $-204M. Revenue grew -60.5% year-over-year compared to FY 2024. Operating income came in at $-215M.

In Q3 2025, Wave Life Sciences Ltd. reported revenue of $8M and earnings per share (EPS) of $-0.32. Net income for the quarter was $-54M. Revenue grew 199.1% year-over-year compared to Q3 2024. Operating income came in at $-56M.

In Q2 2025, Wave Life Sciences Ltd. reported revenue of $9M and earnings per share (EPS) of $-0.31. Net income for the quarter was $-50M. Revenue grew -55.8% year-over-year compared to Q2 2024. Operating income came in at $-53M.

Over the past 8 quarters, Wave Life Sciences Ltd. has experienced revenue contraction from $20M to $18M. Investors analyzing WVE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

WVE Dividend Yield and Income Analysis

Wave Life Sciences Ltd. (WVE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

WVE Momentum and Technical Analysis Profile

Wave Life Sciences Ltd. (WVE) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.

WVE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Wave Life Sciences Ltd. (WVE) ranks #649 out of 838 stocks based on the Blank Capital composite score. This places WVE in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing WVE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full WVE vs S&P 500 (SPY) comparison to assess how Wave Life Sciences Ltd. stacks up against the broader market across all factor dimensions.

WVE Next Earnings Date

No upcoming earnings date has been announced for Wave Life Sciences Ltd. (WVE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy WVE? — Investment Thesis Summary

The quantitative profile for Wave Life Sciences Ltd. suggests caution. The quality score of 17/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. High volatility (stability score 13/100) increases portfolio risk.

In summary, Wave Life Sciences Ltd. (WVE) earns a Reduce rating with a composite score of 30.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on WVE stock.

Related Resources for WVE Investors

Explore more research and tools: WVE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare WVE head-to-head with peers: WVE vs AZN, WVE vs SLGL, WVE vs VMD.